The drug industry set several quarterly records for lobbying spending in the first three months of 2018, but Indianapolis-based Eli Lilly and Co. actually reduced lobbying expenditures.
The Indianapolis pharmaceutical giant is evaluating whether to keep the division, which makes animal-health products, or sell it or take it public. An analyst said it might fetch $16 billion.
The Indianapolis-based drugmaker has several pain medications in the pipeline, including potential treatments for migraine headaches, arthritis and chronic back pain.
A five-year, $7 million program is led and supported by a coalition of local health institutions, including Eli Lilly and Co., Fairbanks School of Public Health and Eskenazi Health. It is based on a model that Lilly has used in other countries.
More than 30 foreign ambassadors—representing countries across four continents—are scheduled to be in Indianapolis to learn about Indiana’s economy and explore potential business relationships with Hoosier firms.
Conner Prairie is teaming with Carmel-based hospitality company Ritz Charles on a $3 million project that will renovate the historic Chinese House at the Fishers living history museum and add an event venue along the White River.
The fact naloxone is a prescription drug creates a hurdle for addicts and their families. In addition, many pharmacies and local health departments don’t stock it, and not everyone can afford it.
The ads for the metastatic breast cancer drug Verzenio show women in their 50s and 60s looking resolute and indomitable, surrounded by smiling friends and family.
Our growing coalition is defining a new vision for this critical infrastructure that joins a national movement that is repurposing aging urban interstates, just like ours, in ways that revitalize cities while still accommodating commuters and growing logistics traffic.
The Indianapolis-based pharmaceutical giant said it plans to acquire ARMO BioSciences Inc., which is working on treatments that activate the immune system of cancer patients to recognize and eradicate tumors.
President Donald Trump is set to unveil his long-awaited plan for reducing drug prices after more than a year of bold promises to tackle pharmacy costs that are squeezing millions of Americans.
President Donald Trump's long-awaited plan to bring down drug prices, unveiled Friday, will mostly spare the pharmaceutical industry he previously accused of "getting away with murder" and instead focus on increasing private competition.
Alex Azar, secretary of Health and Human Services and a former executive of Eli Lilly and Co., said Monday that the Trump administration plans to turn up the heat on uncooperative pharma firms.
